EGFR p.E709_T710delinsD mutation may present with primary resistance and rapid progression on afatinib
Specific Lung Cancer Mutation May Lead to Rapid Treatment Failure
This case report and literature review describes a patient with stage IV lung adenocarcinoma and an EGFR p.E709_T710delinsD mutation who exp…
A specific mutation in lung cancer may cause patients to progress quickly on afatinib, highlighting the need for early monitoring and testin…
Pembrolizumab-induced hypophysitis can cause arginine vasopressin deficiency unmasked by glucocorticoid therapy
Pembrolizumab Treatment Linked to Rare Hormone Deficiency in Lung Cancer
This case report and review describes a patient with metastatic lung adenocarcinoma who developed hypophysitis after pembrolizumab monothera…
A rare case of lung cancer treatment revealed a complex hormone deficiency that only appeared after the patient received steroid therapy.
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
Understanding the Role of PGE2 Signaling in Brain Health and Cancer
This systematic review examines the role of PGE2 signaling across neurological, oncological, and metabolic conditions. The findings indicate…
New research shows how different parts of a single protein pathway can either protect your brain or help tumors grow.
Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers
Protein D shows promise in diagnosing and treating several cancers
This narrative review explores the role of Surfactant protein D (SP-D) across multiple malignancies, including lung adenocarcinoma and breas…
A specific protein called Surfactant protein D may help doctors identify lung cancer and fight cells in breast and leukemia cases.
Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura
New Case Highlights Rare Kidney Risk in Lung Cancer Treatment
This case report and literature review describes a patient with stage IVB lung adenocarcinoma who developed iTTP after receiving an ivonesci…
A single case report identifies a rare blood and kidney condition that can occur during specific lung cancer treatments involving ivonescima…
Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
Combined Treatments May Help Manage Brain Metastases in Lung Cancer
This case report and literature review describes a patient with EGFR-mutant NSCLC and brain/leptomeningeal metastases. The authors suggest t…
A new treatment approach combining surgery, local chemotherapy, and targeted drugs may help manage brain cancer spread for some patients.
Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
Lung cancer can change form after targeted drug treatment
A case report with literature review describes a 71-year-old man with KRAS G12C-mutant lung adenocarcinoma whose tumor transformed to pulmon…
A man's lung cancer transformed into a more aggressive type after taking the targeted drug sotorasib, highlighting the need for re-biopsy wh…
CT-based deep learning models show high accuracy predicting EGFR mutation status in lung adenocarcinoma
Machine learning models help predict lung cancer mutations from scans
This meta-analysis of 6,628 Chinese patients with lung adenocarcinoma found that machine learning-based radiomics models provide a noninvasi…
New analysis shows that deep learning models can accurately identify specific lung cancer mutations using standard CT scans.
Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
High ADAM9 levels linked to worse lung cancer survival in new data
This research article is an observational study with in vitro experiments analyzing TCGA-LUAD datasets from 517 tumor and 59 normal tissues.…
High ADAM9 expression linked to immunosuppression and poorer survival in lung adenocarcinoma patients based on tissue data and lab experimen…
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Toripalimab can induce myositis, myocarditis, and thyroiditis in patients with non-small cell lung cancer
Toripalimab Treatment Linked to Heart and Muscle Inflammation
This case report and literature review describes a 74-year-old male with stage IIIA lung squamous cell carcinoma who developed multiple immu…
A single case study shows a patient with lung cancer developed heart and muscle inflammation after receiving toripalimab treatment.
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
Icotinib Treatment for Lung Cancer Linked to Rare Blood Condition
This case report and literature review describes a 75-year-old female with lung adenocarcinoma treated with icotinib. The report identifies …
A rare case of acute myeloid leukemia was linked to a specific lung cancer treatment, highlighting the need for regular blood monitoring.
NLRP3 signaling and IL-1β inhibition show context-dependent roles in non-small cell lung cancer
IL-1β Inhibition Shows Potential in Non-Small Cell Lung Cancer
This narrative review synthesizes experimental and clinical data regarding NLRP3 signaling and IL-1β inhibition in non-small cell lung cance…
New research explores how blocking specific inflammatory pathways might influence the environment of non-small cell lung cancer.
First-line EGFR inhibitor options for advanced NSCLC require balancing efficacy with patient-centered tolerability trade-offs
New Treatment Options for Lung Cancer Patients with EGFR Mutations
This narrative review examines first-line therapy options for patients with advanced EGFR-mutated non-small cell lung cancer. The authors co…
Newer first-line therapies for lung cancer offer more options, but doctors must balance the strength of the drug against how well a patient …
miR-155 overexpression is frequently associated with treatment resistance across 8 cancer types
miR-155 Expression Linked to Treatment Resistance in Various Cancers
This systematic review of 19 studies across 8 cancer types indicates that miR-155 overexpression is associated with treatment resistance in …
Research suggests that high levels of a specific molecule, miR-155, may be linked to how well certain cancers respond to treatment.
PD-1/PD-L1 inhibitors with SRS or FSRT achieve 87% one-year local control in brain metastases
Combining immunotherapy and radiation for brain metastases shows promise
This meta-analysis of 2587 patients with brain metastases evaluated the combination of PD-1/PD-L1 inhibitors with stereotactic radiosurgery …
A new analysis shows that combining specific immunotherapy drugs with radiation can help control brain tumors and manage side effects.
TCM combined with EGFR-TKIs significantly improves progression-free survival in advanced EGFR-mutant NSCLC
Traditional Chinese medicine may improve survival for certain lung cancers
This meta-analysis evaluates the impact of traditional Chinese medicine (TCM) combined with EGFR-TKIs in patients with advanced EGFR-mutant …
Combining traditional Chinese medicine with targeted therapies may help patients with a specific type of lung cancer live longer without the…
mRNA vaccines provide a clinically validated platform to induce durable anti-tumor immunity in solid tumors
mRNA Vaccines Show Potential for Treating Several Solid Tumors
This systematic review evaluates mRNA vaccines for melanoma, pancreatic cancer, and non-small cell lung cancer. The authors conclude that mR…
mRNA technology is being used to create cancer vaccines that may help patients with melanoma, pancreatic, and lung cancers by building lasti…
Antibody-drug conjugates are expanding from late-line to first-line combination regimens in lung cancer
New Drug Class Shifts Lung Cancer Treatment Toward First-Line Use
This narrative review examines the expanding role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and small cell lu…
A new class of cancer drugs is moving from last-resort treatment to first-line therapy for lung cancer, but early data need confirmation.
Serplulimab induced grade 4 checkpoint inhibitor pneumonitis in an elderly patient with SCLC and COPD
New cancer treatment causes severe lung inflammation in elderly patients
This case report describes a grade 4 serplulimab-induced checkpoint inhibitor pneumonitis in an 80-year-old man with extensive-stage small c…
A new cancer drug caused severe, life-threatening lung inflammation in an 80-year-old man with existing lung disease.
Later-line antibody-drug conjugates show 25.7% objective response rate in advanced small-cell lung cancer
Antibody-drug conjugates show activity in advanced small-cell lung cancer
This systematic review and meta-analysis evaluates later-line monotherapy with antibody-drug conjugates (ADCs) for advanced small-cell lung …
Antibody-drug conjugates show promise for treating advanced small-cell lung cancer, though they are associated with frequent clinical toxici…
Atezolizumab with SBRT fails to improve survival in early NSCLC
Trial shows atezolizumab plus SBRT does not improve lung cancer survival
Adding atezolizumab to stereotactic body radiotherapy did not improve overall survival in inoperable early-stage NSCLC, while increasing sev…
A large phase 3 trial found that adding the immunotherapy drug atezolizumab to SBRT did not improve survival for patients with inoperable lu…
Questions about Lung Adenocarcinoma
How does gene expression affect survival in early-stage lung adenocarcinoma?
Gene expression programs involving immune cells, stromal remodeling, and acylation modifications significantly predict survival and recurrence in early-stage lung adenocarcinoma.
Full answer →Can aumolertinib be used again after osimertinib causes lung problems?
Yes, aumolertinib (almonertinib) has been successfully used after osimertinib caused lung problems like interstitial lung disease, based on case reports.
Full answer →All Lung Adenocarcinoma Articles
- EGFR p.E709_T710delinsD mutation may present with primary resistance and rapid progression on afatinib
- Pembrolizumab-induced hypophysitis can cause arginine vasopressin deficiency unmasked by glucocorticoid therapy
- KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
- PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
- Surfactant protein D serves as a prognostic marker and potential therapeutic agent in various cancers
- Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura
- Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
- Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
- CT-based deep learning models show high accuracy predicting EGFR mutation status in lung adenocarcinoma
- Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
- Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
- Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
- Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
- Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
- Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
- Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
- Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
- NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models
- Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
- Predictive nomogram with spectral CT radiomics and deep learning features improves preoperative STAS prediction in surgically resected lung adenocarcinoma
- AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients
- Radiomics-ML model predicts invasiveness in subcentimeter subsolid lung adenocarcinoma
- CT-based radiomics shows variable accuracy for predicting occult lymph node metastasis in early-stage lung adenocarcinoma